Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1938]

Managing high-risk/MRD positive and standard-risk/MRD myeloma

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Managing high-risk/MRD positive and standard-risk/MRD myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Minimum residual disease techniques in myeloma

Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy

Minimum residual disease techniques in myeloma ( Dr Stefania Oliva - GIMEMA, European Myeloma Network, Italy )

Identifying and treating high-risk/MRD positive newly diagnosed multiple myeloma

Prof Wee Joo Chng - National University Cancer Institute, Singapore

Identifying and treating high-risk/MRD positive newly diagnosed multiple myeloma ( Prof Wee Joo Chng - National University Cancer Institute, Singapore )

High-risk SMM imaging and NDMM treatment

Dr Elena Zamagni - University of Bologna, Bologna, Italy

High-risk SMM imaging and NDMM treatment ( Dr Elena Zamagni - University of Bologna, Bologna, Italy )

Rescue after daratumumab failure

Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix...

Rescue after daratumumab failure ( Prof Joseph Mikhael - Translational Genomics Research Institute (TGen), Phoenix, USA )

MRD-driven strategies and novel immunotherapies for multiple myeloma

Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia

MRD-driven strategies and novel immunotherapies for multiple myeloma ( Prof Simon Harrison - Peter MacCallum Cancer Centre, Melbourne, Australia )

How to approach pain management in myeloma patients

Prof Wolfgang Grisold - Medical University of Vienna, Vienna, Austria

How to approach pain management in myeloma patients ( Prof Wolfgang Grisold - Medical University of Vienna, Vienna, Austria )

Refractoriness and retreatment in the era of lenalidomide and mABs in the...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Refractoriness and retreatment in the era of lenalidomide and mABs in the frontline myeloma setting ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed...

Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway

$Melflufen and dexamethasone vs pomalidomide and dexamethasone in relapsed refractory multiple myeloma ( Dr Fredrik Schjesvold - Oslo Myeloma Center, Oslo, Norway )$

New MM patients with high levels of circulating tumour cells distinguished by...

Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands

New MM patients with high levels of circulating tumour cells distinguished by increased bone marrow plasma cell proliferation ( Dr Cathelijne Fokkema - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Novel therapies in multiple myeloma

Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Novel therapies in multiple myeloma ( Dr Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

Disparities in myeloma: Closing the gap

Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA

Disparities in myeloma: Closing the gap ( Prof Joseph Mikhael - Translational Genomics Research Institute, Pheonix, USA )

More from ecancer